To investigate the patient‐perceived reasons for initiation, perceived benefits, side effects experienced and willingness to continue or restart adjuvant treatment with GLP‐1 RA or SGLT2i in patients with T1DM. The gene discussed is GCG; the disease is type 1 diabetes mellitus.